Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system.

4 More recently, the 2025 American Society of Clinical Oncology annual meeting reported long-term follow-up from CheckMate 577, which confirmed sustained DFS benefit and showed a numerical improvement in OS with adjuvant nivolumab (median OS 51.7 vs 35.3 months), though the difference did not reach statistical significance. 12 These findings further support the role of adjuvant nivolumab.

also in 111,027 other papers